GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (STU:HAZ) » Definitions » Cyclically Adjusted Price-to-FCF

Haemonetics (STU:HAZ) Cyclically Adjusted Price-to-FCF : 48.20 (As of May. 24, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Haemonetics Cyclically Adjusted Price-to-FCF?

As of today (2024-05-24), Haemonetics's current share price is €80.50. Haemonetics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €1.67. Haemonetics's Cyclically Adjusted Price-to-FCF for today is 48.20.

The historical rank and industry rank for Haemonetics's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

STU:HAZ' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 28.1   Med: 46.08   Max: 112.62
Current: 48.5

During the past years, Haemonetics's highest Cyclically Adjusted Price-to-FCF was 112.62. The lowest was 28.10. And the median was 46.08.

STU:HAZ's Cyclically Adjusted Price-to-FCF is ranked worse than
57.89% of 228 companies
in the Medical Devices & Instruments industry
Industry Median: 44.5 vs STU:HAZ: 48.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Haemonetics's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €0.974. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €1.67 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Haemonetics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Haemonetics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Cyclically Adjusted Price-to-FCF Chart

Haemonetics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 76.65 85.65 45.03 47.61 45.94

Haemonetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.61 47.98 47.17 48.21 45.94

Competitive Comparison of Haemonetics's Cyclically Adjusted Price-to-FCF

For the Medical Instruments & Supplies subindustry, Haemonetics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Haemonetics's Cyclically Adjusted Price-to-FCF falls into.



Haemonetics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Haemonetics's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=80.50/1.67
=48.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Haemonetics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.974/131.7762*131.7762
=0.974

Current CPI (Mar. 2024) = 131.7762.

Haemonetics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.332 100.560 -0.435
201409 -0.038 100.428 -0.050
201412 -0.043 99.070 -0.057
201503 0.594 99.621 0.786
201506 -0.260 100.684 -0.340
201509 0.028 100.392 0.037
201512 0.147 99.792 0.194
201603 0.436 100.470 0.572
201606 0.143 101.688 0.185
201609 0.347 101.861 0.449
201612 0.661 101.863 0.855
201703 0.341 102.862 0.437
201706 0.416 103.349 0.530
201709 0.689 104.136 0.872
201712 0.618 104.011 0.783
201803 0.577 105.290 0.722
201806 -0.072 106.317 -0.089
201809 0.143 106.507 0.177
201812 0.481 105.998 0.598
201903 0.117 107.251 0.144
201906 -0.098 108.070 -0.119
201909 0.356 108.329 0.433
201912 1.026 108.420 1.247
202003 0.631 108.902 0.764
202006 0.071 108.767 0.086
202009 0.346 109.815 0.415
202012 0.911 109.897 1.092
202103 -0.165 111.754 -0.195
202106 -0.254 114.631 -0.292
202109 0.374 115.734 0.426
202112 0.617 117.630 0.691
202203 0.582 121.301 0.632
202206 -0.064 125.017 -0.067
202209 1.001 125.227 1.053
202212 0.877 125.222 0.923
202303 1.234 127.348 1.277
202306 0.169 128.729 0.173
202309 1.358 129.860 1.378
202312 -0.407 129.419 -0.414
202403 0.974 131.776 0.974

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Haemonetics  (STU:HAZ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Haemonetics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Haemonetics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics (STU:HAZ) Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Haemonetics (STU:HAZ) Headlines

No Headlines